Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc (A) delivers cutting-edge analytical instruments and laboratory solutions for scientific advancement across biopharmaceutical, diagnostic, and environmental sectors. This page provides investors and industry professionals with a centralized source for all official company announcements and market-relevant developments.
Access real-time updates on Agilent's financial performance, strategic partnerships, product innovations, and regulatory milestones. Our curated news collection includes earnings releases, executive leadership updates, R&D breakthroughs, and industry event coverage—all essential for tracking the company's impact on life sciences and laboratory technology.
Key focus areas include advancements in genomic research tools, sustainability initiatives in lab operations, and cross-sector collaborations driving scientific discovery. Bookmark this page to stay informed about Agilent's evolving role in enabling precision medicine, environmental testing, and next-generation materials analysis.
Agilent Technologies (NYSE: A) has awarded the 2024 Early Career Professor Award to Dr. Adeyemi Adeleye from Columbia University for his contributions to environmental health and sustainability. Dr. Adeleye's research focuses on using engineered nanoparticles made of earth-abundant elements to remediate environmental contamination from pollutants like arsenic, lead, and PFAS. His work also explores combining remediation with carbon sequestration to reduce environmental impact. The research supports FDA and USDA initiatives to address toxic heavy metals in crop-based foods through the 'Closer-to-Zero' Initiative, with additional support from NSF and CDC.
Agilent Technologies (NYSE: A) has been ranked #11 on Fortune's Best Workplaces in the World list, among 25 companies. The ranking is based on the Great Place to Work survey, which collected 7.4 million responses representing 20 million employees globally. The company stands out for its comprehensive employee programs focusing on well-being, professional development, and community engagement.
Notable initiatives include paid volunteer time, fitness programs tailored to different regions, and Employee Network Groups. Agilent offers extensive educational resources, mentorship opportunities, and supports charitable giving by matching employee donations up to $25,000 annually. The company also compensates employees for volunteer hours with $25 per hour that can be donated to eligible charities.
Agilent Technologies (NYSE: A) has launched the Mito-rOCR Assay Kit, a new solution for analyzing mitochondrial function in cells. This innovative kit measures cells' relative oxygen consumption rate (rOCR), providing insights into mitochondrial health and performance. The assay is compatible with various fluorescent plate readers and multimode imagers, including the BioTek Cytation series. Key features include direct compound reconstitution in assay medium, reversibility, and integration with Agilent Seahorse Analytics cloud-based software for streamlined data analysis. The kit aims to democratize cell analysis by making sophisticated mitochondrial research accessible to researchers of all skill levels.
Agilent Technologies (NYSE: A) has awarded its Solutions Innovation Research Award (SIRA) to Professor Isabelle Plante from INRS and Professor Bangyan Stiles from USC for their cell and gene therapy research. Professor Plante's research focuses on breast cancer mechanisms and environmental pollutants, while Professor Stiles studies lipid metabolic dysfunction in cancer formation. Both recipients will receive one-year loans of various Agilent instruments including the NovoCyte Penteon flow cytometer. The SIRA initiative, established in 2023, aims to support innovative academic research using Agilent's analytical solutions.
Crawford & Company (NYSE: CRD-A and CRD-B) announced that its Board of Directors has declared a quarterly dividend of $0.07 per share for both Class A and Class B Common Stock. The dividend will be paid on December 6, 2024, to shareholders of record as of the close of business on November 19, 2024. The declaration was made during the company's regular quarterly board meeting on October 31, 2024.
Agilent Technologies Inc. (NYSE: A) has unveiled its next-generation Agilent InfinityLab LC Series portfolio, featuring the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems. These are the first HPLC systems to incorporate the new Agilent InfinityLab Assist Technology, offering enhanced built-in system assistance capabilities.
The new LC systems significantly improve task automation, connectivity, predictive feedback, and error reduction. They include innovative built-in sample tracking with barcoding and camera technologies to eliminate sample mix-ups. The InfinityLab Assist automates instrument routines, simplifies sample preparation, assists with maintenance and troubleshooting, and provides context-sensitive help content.
The Infinity III LC Series also features method compatibility with earlier LC systems, seamless chromatography data systems integration, and third-party verification by My Green Lab's revised ACT 2.0 Ecolabel. They will be the first LC systems to provide their CO2 footprint to customers, demonstrating Agilent's commitment to environmental sustainability.
Agilent Technologies Inc. (NYSE: A) has announced that it will release its fourth-quarter fiscal year 2024 financial results after the stock market closes on Monday, Nov. 25. The company will also host a conference call to discuss the results at 1:30 p.m. PST on the same day.
Investors and interested parties can join the listen-only conference call webcast by clicking the link provided on the Events section of Agilent's investor relations website. For those unable to attend the live call, a recording will be available on the website for 90 days following the event.
Agilent Technologies Inc. (NYSE: A) has announced an upcoming Analyst and Investor Day scheduled for Tuesday, Dec. 17, 2024, at 10 a.m. ET in New York City. The event will feature presentations from key company leaders, including CEO Padraig McDonnell and CFO Bob McMahon, who will discuss:
- Agilent's strategy
- Business operations
- Long-term financial outlook
The event will conclude with a Q&A session. While attendance is by invitation only, a live webcast will be available through Agilent's Investor Relations website. A replay of the event will remain accessible for at least 60 days following the presentation.
H.I.G. Capital has announced the sale of its portfolio company, BIOVECTRA Inc., to Agilent Technologies, Inc. (NYSE: A) for $925 million. BIOVECTRA, a leading contract development and manufacturing organization (CDMO) of active pharmaceutical ingredients and intermediates, is headquartered in Charlottetown, Prince Edward Island, Canada. The company has approximately 650 employees and eight facilities with over 270,000 square feet of space.
H.I.G. acquired BIOVECTRA in November 2019 and successfully established it as an independent organization. Under H.I.G.'s ownership, BIOVECTRA strengthened its executive management team, completed three major facility build-outs, and significantly grew its sales pipeline while focusing more on commercial products. These strategic initiatives resulted in an industry-leading growth profile and an outstanding outcome for shareholders.
Agilent Technologies Inc. (NYSE: A) has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) specializing in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition, now part of Agilent's Diagnostics and Genomics Group, expands Agilent's portfolio of CDMO services and adds rapidly growing modalities to support gene editing.
Agilent CEO Padraig McDonnell emphasized the company's commitment to providing advanced capabilities for accelerating therapeutics programs. The transaction is expected to be $0.05 dilutive to non-GAAP earnings per share (EPS) in the first full year after closing but is projected to deliver a double-digit return on invested capital (ROIC) by year five. Agilent funded the acquisition using a mix of cash on hand and debt financing.
